Single-dose Efficacy of a Next-Generation Mpox Vaccine Harnessing an Immunomodulatory Peptide
Anoli Karunathilake, Reem Miah, Crystal A. Lawson, JD Burleson, Sreenivasa RaoOruganti, Mary J. Hauser, Arban Domi, Brooklyn Adragna, Brayden Olsen, Shuangyi Bai, Pratima KumariiD, Bronwyn M. GunniD, Mark Newman, Heather S. KoehleriD
Abstract
Rapidly deployable, single-dose vaccines that maintain durability under operational constraints remain an unmet need in outbreak preparedness. Live viral vectors such as Modified Vaccinia Ankara (MVA) offer strong safety profiles, yet their suboptimal immunogenicity often requires multidose regimens, reducing flexibility during emergency response. To address these limitations, we developed a modular vaccine platform that leverages immune checkpoint modulation to enhance immune cell priming without compromising the established safety profile of MVA. This platform, exemplified by the recombinant virus MVA-X, was engineered to express a peptide-based PD-1 antagonist (LD10) that provides localized, transient checkpoint blockade during early antigen presentation. The approach requires no external adjuvants, is compatible with lyophilization and stockpiling, and is readily adaptable to diverse antigens and pathogens. A single immunization with MVA-X produced durable protection that matched or exceeded that of a conventional two-dose MVA regimen against the prototypic orthopoxvirus vaccinia virus. Despite modest and contracting antibody titers, single-dose MVA-X vaccination conferred complete survival following both lethal and high-dose viral challenge at early (Day 55), intermediate (Day 90), and long-term (Day 150) time points. MVA-X also restricted viral replication at the primary site of infection, reduced systemic dissemination, and preserved lung architecture during peak disease. Importantly, MVA-X maintained efficacy in the highly susceptible CAST/EiJ mouse model following challenge with highly pathogenic Clade I monkeypox virus (MPXV). Together, these findings demonstrate that vaccine-intrinsic checkpoint modulation provides a modular strategy for enhancing the potency and durability of attenuated viral vectors while preserving their favorable safety profile, supporting broader application to emerging infectious diseases beyond Mpox.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge
A. W. Freyn, C. Atyeo, … B. Moss·bioRxiv·Dec 17, 2022
- Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus
- Polyvalent mRNA vaccination elicited potent immune response to monkeypox surface antigens
Z. Fang, P. A. Renauer, … S. Chen·bioRxiv·Nov 29, 2022
- Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge
- Mpox mRNA-1769 Vaccine Inhibits Orthopoxvirus Replication at Intranasal, Intrarectal, and Cutaneous Sites of Inoculation
Catherine A. Cotter, Maxinne A. Ignacio, … Bernard Moss·npj VaccinesPeer-reviewed·Dec 24, 2024
- Potent Neutralization by Antibodies Targeting the Mpox A28 Protein
Ron Yefet, Leandro Battini, … Natalia Tarnovitski Freund·bioRxiv·May 22, 2025